Toro

Quick links to important sections

Toro

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Toro

Property Description
Active Ingredient Ofloxacin (C18H20FN3O4)
Form Tablet (oral), Ophthalmic Solution (eye), Otic Solution (ear)
Pharmacological Class Second-generation fluoroquinolone antibiotic
Common Use Elimination of susceptible bacterial pathogens
Origin Synthetic (chemically manufactured)

Defining Toro: A Fluoroquinolone Antibacterial Agent

The pharmaceutical product Toro is a trade name for the active ingredient Ofloxacin, which is classified as an essential second-generation fluoroquinolone antibiotic. This designation places it within the broader group of antimicrobial agents used to eliminate susceptible bacterial pathogens, and Ofloxacin is recognized as an essential medicine. The drug is a prescription-only (Rx) product, reflecting the critical need for physician oversight in antimicrobial therapy. The medicine's availability in multiple dosage forms, including the tablet for oral (systemic) administration and specialized topical solutions (ophthalmic/otic), allows clinicians to target infections appropriately.


Composition and Origin: The Synthetic Nature of Ofloxacin

Toro is primarily a single-ingredient product, relying on the sole active compound Ofloxacin. This compound is a synthetic antimicrobial agent, meaning it is reliably manufactured through controlled chemical processes, rather than being naturally derived. This synthetic origin helps ensure consistent purity and predictable potency. Ofloxacin is used to treat a variety of bacterial infections in humans. The physical preparation dictates the base: the oral tablet contains solid excipients, while the topical solutions use an aqueous solution base, facilitating targeted delivery to areas like the ear or eye.


General Therapeutic Purpose of This Agent

The core purpose of this medicine is to act as a powerful bactericidal agent, meaning it actively works to eliminate bacteria that cause infections by disrupting their critical DNA replication processes. This action makes Ofloxacin a broad-spectrum compound, designed to be effective against a wide range of different bacterial species. The primary therapeutic benefit lies in resolving the underlying microbial cause of an issue, providing a reliable method for managing bacterial infections.

Regulatory References

  1. World Health Organization

What side effects are possible with Toro?

Official Adverse Reactions and Safety Profile

The safety profile of Toro (Ofloxacin), a systemic fluoroquinolone, is formally classified in regulatory documents by the organ system affected and the frequency of occurrence. Common adverse reactions, officially classified as Uncommon (occurring in 1/1,000 to <1/100 patients), typically involve the Gastrointestinal system, such as nausea and diarrhea, or the Nervous System, including headache and dizziness.


Serious and Potentially Irreversible Reactions

Official government warnings emphasize the potential for serious adverse reactions, many of which are officially documented as disabling and potentially long-lasting or irreversible. These include severe effects on the Musculoskeletal and Connective Tissue Disorders (e.g., Tendon Rupture and Tendinitis), and the Nervous System (e.g., Peripheral Neuropathy, characterized by pain, tingling, or weakness). These serious reactions may occur rapidly, sometimes within 48 hours of starting treatment, or be delayed several months after stopping the medication.


Population-Specific Safety Constraints

Regulatory documentation mandates specific considerations for certain patient groups. Older adults and patients concurrently using corticosteroids are officially noted as having an increased risk of tendon damage. The medication should be avoided in patients with a history of Myasthenia Gravis (due to possible exacerbation of muscle weakness) or in individuals with known QT interval prolongation (due to increased risk of serious arrhythmias, such as Torsades de pointes). Use is restricted in patients with severe renal impairment due to reduced drug clearance and heightened safety risks.

Overdose and Emergency Response

Overdose and when to seek help

The following information on overdose manifestations and emergency response is strictly derived from official government regulatory sources for Ofloxacin (Toro).

Feature Official Regulatory Statements
Documented overdose presentations Overexposure may lead to symptoms including drowsiness, nausea, dizziness, confusion, slurred speech, and numbness and swelling of the face [MedlinePlus Drug Information].
Physiological systems affected Toxicity may affect the Central Nervous System (CNS), with risk of convulsions/seizures. Severe outcomes may also involve the cardiovascular system (e.g., QT interval prolongation) and lead to hepatic failure or life-threatening shock from acute reactions [NAFDAC Summary of Product Characteristics].
Population-specific overdose notes Patients with severe renal impairment require enhanced monitoring due to increased risk of drug accumulation and potential toxicity [NAFDAC Summary of Product Characteristics].
Emergency-response statements Symptomatic and supportive treatment is the officially described management approach, as no specific antidote is known. EKG monitoring may be required [NIH StatPearls on Ofloxacin].
When immediate medical help is required It is officially mandated to seek immediate medical attention for suspected overdose or the manifestation of severe, potentially life-threatening symptoms, and to stop treatment immediately at the first signs of convulsive seizures or liver disease [MedlinePlus Drug Information].

Official regulatory documents define the Ofloxacin overdose profile by listing specific CNS and GI manifestations that signal acute overexposure. This profile underscores the need for immediate action due to the potential for severe, life-threatening events like seizures, shock, and cardiac instability, mandating that immediate medical help be sought exactly as detailed in the official prescribing information.

Therapeutic Uses of Toro

Main Uses and Therapeutic Benefits

Toro (Ofloxacin) is an antibacterial agent used for managing conditions caused by susceptible bacterial pathogens that lead to infections across multiple body systems. It is relevant for easing symptoms in conditions such as pneumonia, bronchitis, urinary tract infections (UTIs), skin infections, and specific infections of the reproductive organs (e.g., Pelvic Inflammatory Disease). The therapeutic benefit centers on addressing conditions that present with significant symptomatic burden to provide supportive relief during acute episodes.

This medication is applied in contexts marked by increased discomfort and helps address symptom clusters that may become intense or disruptive. This includes symptoms related to localized pain (like dysuria or otalgia), abnormal discharge (such as purulent discharge), and signs of heightened physiological activity (like redness or swelling).

The specialized topical solutions are commonly used in scenarios requiring short-term symptomatic assistance for Otitis Externa, middle ear infections with tubes, bacterial Conjunctivitis, and serious Corneal Ulcers.

“It is commonly used across conditions presenting with acute episodes and helps manage symptoms that interfere with daily comfort.”


Quick Fact: May assist with Inflammatory Discomfort

The application of Ofloxacin in these diverse areas provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during periods of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview on Ofloxacin

Eligibility and Restrictions for Use

The eligibility for using Toro (Ofloxacin) is strictly defined by regulatory authorities based on patient age, medical history, and physiological status. Eligibility is conditional on the formulation: the systemic (oral) form is generally restricted to adults (18 years and older), while topical solutions (otic/ophthalmic) are approved for use in children aged 1 year and older.


Contraindicated Populations (Must Not Use)

Official prescribing information prohibits the use of Toro in the following groups:

  • Patients with a history of hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotic.
  • Individuals with a history of epilepsy or a pre-existing central nervous system disorder that lowers the seizure threshold.
  • Patients with a history of tendon disorders related to previous use of a fluoroquinolone.
  • Systemic use is contraindicated in pregnant and breastfeeding women by some authorities due to potential risks.
  • Patients with a known history of Myasthenia Gravis.

Populations Requiring Conditional Use

Use in these groups is permitted but requires special caution and/or dosage adjustment:

  • Patients with renal impairment (creatinine clearance le 50 mL/min), as drug clearance is reduced and dosage adjustment is necessary.
  • Patients with hepatic impairment, where caution is advised due to potential reduced drug elimination.
  • Older adults ( ge 60 years), particularly those with concurrent renal impairment or who are taking systemic corticosteroids, due to an increased risk of tendon problems.
  • Patients with known or family history of QT interval prolongation or arrhythmias.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic and Pharmacodynamic Interaction Patterns

Officially documented interactions for Toro (Ofloxacin) primarily involve effects on drug exposure and additive pharmacodynamic risks. Products containing polyvalent cations such as magnesium/aluminum antacids, sucralfate, iron, and zinc can significantly decrease Ofloxacin absorption. To mitigate this absorption interference, the oral Ofloxacin tablet must not be taken within two hours before or two hours after administration of these cation-containing preparations.

Conversely, drugs that compete for active renal tubular transport, such as Probenecid, cimetidine, furosemide, and methotrexate, reduce Ofloxacin clearance and can increase its systemic exposure (AUC).

Documented Pharmacodynamic Effects

Co-administration with agents that share certain effects carries risk due to pharmacodynamic summation. Ofloxacin increases the likelihood of convulsive seizures when taken concurrently with agents that lower the seizure threshold, including theophylline and certain non-steroidal anti-inflammatory drugs (NSAIDs) like fenbufen. There is also an increased risk of serious arrhythmia when combined with medicinal products known to prolong the QT interval, such as Class IA and Class III antiarrhythmics, tricyclic antidepressants, and macrolides. Additionally, Ofloxacin use with warfarin may increase the anticoagulant effect and lead to elevated PT/INR results. In specific populations, Ofloxacin clearance is reduced in patients with renal impairment, potentially heightening the severity of documented interactions due to increased drug exposure.

Mechanism of Action

Blocking Bacterial DNA Management Enzymes

Ofloxacin is a selective inhibitor of two critical bacterial enzymes: DNA Gyrase and Topoisomerase IV. By binding to and stabilizing the cleavable complex formed by the enzyme and the DNA, the compound locks the bacterial genome in a state of continuous, irreparable double-strand breaks. This inhibition prevents the necessary unwinding, relaxing, and separation of the DNA helix, which are processes essential for replication and transcription.


Initiating the Irreversible Bactericidal Cascade

The accumulation of lethal DNA breaks overwhelms the bacterial cell's repair mechanisms, triggering an immediate and irreversible bactericidal (cell-killing) cascade. This action causes irreparable damage to the cell's genetic integrity and halts all microbial proliferation, resulting in the irreversible destruction of the susceptible pathogen population.


Understanding Mechanism Limitations and Selectivity

The mechanism relies on a differential binding affinity for bacterial enzymes compared to analogous human enzymes. However, the mechanism is limited by acquired resistance, where mutations in the enzyme structure or the action of bacterial efflux pumps can reduce Ofloxacin's intracellular concentration, thus weakening the cytotoxic effect required for bacterial cell death.

Dosage and Administration Information

Administration Overview

Toro is a medication designed for specific therapeutic use. Proper administration is essential to ensure the medication is delivered as intended. The process typically involves preparation of the medication, selection of an appropriate administration site, and following a consistent routine.

Preparation

Before use, it is important to inspect the medication. The solution should be checked for clarity and the absence of particles. If the medication appears cloudy or contains visible debris, it should not be used. Ensure all necessary materials are gathered in a clean, well-lit workspace.

General Usage Principles

  • Consistency: Taking the medication at the same time each day helps maintain steady levels in the body.
  • Site Rotation: If the medication is administered via injection, rotating the site of administration is a standard practice to maintain skin health and ensure proper absorption.
  • Hygiene: Thorough handwashing and cleaning the area of administration are foundational steps in the process.

Storage and Handling

The integrity of the medication depends on adhering to storage requirements. Exposure to extreme temperatures or direct light should be avoided. Always keep the medication in its original packaging until it is ready for use to protect it from environmental factors.

Recent Clinical Evidence

Research evidence / Overview of studies for Toro (Ofloxacin)

This overview describes the scope of clinical research conducted for Ofloxacin, including the types of studies, what outcomes were monitored, and what uncertainties remain, according to official regulatory and scientific literature.


Evidence for Use in Urinary Tract Infections (UTIs)

Research exploring Ofloxacin for conditions characterized by acute or disruptive episodes, such as UTIs, includes numerous Randomized Controlled Trials (RCTs) and systematic reviews. Studies were conducted in adults with both uncomplicated UTIs and those with specific co-occurring conditions. Researchers monitored primary outcomes related to systemic or functional imbalance, specifically looking at the rate of bacterial elimination (Bacteriologic Outcome Rate) and the measured change in acute signs like painful or frequent urination (Clinical Outcome Rate) at the end of the treatment period. One key limitation noted is the rising scientific documentation of emerging bacterial resistance to fluoroquinolone antibiotics.


Evidence for Use in Respiratory Tract Infections

Studies examining Ofloxacin for conditions involving periods of heightened symptoms, like certain lower respiratory tract infections (LRTIs), consist of various controlled trials and open-label studies. These research efforts focused on adult populations. Researchers primarily monitored the Clinical Response Rate—a metric tracking the measured change in symptoms such as cough and fever—and the documentation of bacterial elimination from the infection site. Comparative evidence exists, but findings were mixed in some systematic reviews regarding the clinical response compared to newer antibiotic agents.


Evidence for Use in Topical Ocular and Otic Infections

The use of Ofloxacin solutions applied directly to the site of infection in the eye and ear has been evaluated in specialized research, including Double-Masked Clinical Trials for the eye and Multicenter Trials for the ear. These studies were applied in research exploring short-term symptom changes. Outcomes monitored included the reduction of redness and inflammation, alongside measuring microbiologic elimination. Studies documented that measured outcomes in key trials were comparable to those of other anti-infective agents in the measured short-term microbiological and clinical endpoints.


What Research Gaps and Uncertainties Remain

The clinical evidence primarily reflects short-term follow-up durations that align with the acute nature of the infections it addresses. The available data for long-term outcomes remains insufficient, meaning the research provides context but not individual predictions about the sustained effect or the risk of infection recurrence well after treatment completion. The certainty remains low regarding the activity of Ofloxacin against bacterial strains that have developed increasing resistance, which is a key limitation of the evidence.

Key Studies & References

  1. FLOXIN® Otic (Ofloxacin Otic) Solution 0.3% Package Insert for Otic Use (Pediatric/Adult Indications)
  2. [Respiratory tract infections--clinical results with ofloxacin] (Includes data on acute bronchitis and pneumonia)
  3. WHO Model List of Essential Medicines - Ofloxacin entry and supporting evidence reviews for topical ophthalmological use

Frequently Asked Questions (FAQ)

Common questions about Toro (FAQ)


Q: What conditions does the FDA specifically approve Toro to treat?

Official information from the U.S. Food and Drug Administration (FDA) indicates that the oral tablet form of Toro (Ofloxacin) is approved to treat specific types of bacterial infections. These may include certain infections of the skin, lower respiratory tract (like bronchitis or pneumonia), urinary tract, and certain sexually transmitted infections.


Q: How quickly does Toro usually start working?

Regulatory information indicates that the drug typically reaches its maximum concentration in the bloodstream approximately one to two hours after taking the oral tablet. Researchers in clinical studies monitor measured changes in acute signs and symptoms over the full prescribed course of treatment.


Q: How long does Toro stay in the system after the last dose?

Official pharmacokinetic studies describe how the body processes the drug. The average terminal elimination half-life of Ofloxacin is generally reported to be around four to five hours. The half-life refers to the time it takes for the concentration of the medicine in the blood to decrease by half.


Q: Is there a generic version of Toro available?

Yes. Toro is the brand name for the active ingredient Ofloxacin. Ofloxacin is widely available as a generic medicine. The FDA considers generic versions of Ofloxacin to be therapeutically equivalent to the brand-name product.


Q: What is the difference between the brand-name Toro and its generic?

Toro is the trade name, while Ofloxacin is the official active ingredient. Generic versions of Ofloxacin contain the exact same active ingredient, dose, and strength as the brand-name product. Regulatory agencies, such as the FDA, consider them to work the same way in the body.


Q: Are there different strengths of the Toro pill available?

Official dosage guides indicate that the oral tablet formulation of Toro (Ofloxacin) is manufactured in several different strengths. These strengths may include 200 mg, 300 mg, and 400 mg tablets, depending on the manufacturer and the country's jurisdiction.


Q: What happens if I miss a dose of Toro?

General patient education materials derived from official sources describe standard guidelines for handling a missed dose. These guidelines often state that if a dose is forgotten, it should be addressed promptly, unless it is close to the next scheduled dose, in which case the forgotten dose is typically skipped. Patients are generally advised not to take extra medication to make up for a missed dose.


Q: What happens when you stop taking Toro?

Regulatory agencies often emphasize the importance of completing the entire course of antibacterial therapy as prescribed. Official documents also indicate that certain serious adverse reactions, such as tendon issues or peripheral neuropathy, may be delayed and can occur even several months after the medication has been stopped.


Q: Is Toro safe to use long-term?

Official regulatory documents indicate that the systemic (oral) use of Toro is generally intended for short-term treatment and is typically limited to two months. Clinical studies primarily focus on short-term outcomes. Warnings also emphasize that potential serious effects, such as tendon damage, may be long-lasting or irreversible.


Q: What foods or drinks should be avoided while taking Toro?

The oral tablet can be administered with or without food. However, it is officially required to separate the tablet by at least two hours from products containing polyvalent metal cations, such as antacids, iron supplements, or zinc. Official studies on this drug also indicate that it does not significantly affect the elimination of caffeine from the body.


Q: Can Toro interact with supplements like vitamins or herbal products?

Toro is officially known to interact with products containing metal cations (like magnesium, iron, zinc, and calcium), which are commonly found in certain vitamins and mineral supplements. These cations can significantly decrease the amount of Toro absorbed by the body. The tablet must be taken separately from these products.


Q: Can Toro be taken with pain relievers like ibuprofen?

Official drug interaction warnings state that Toro (ofloxacin) may increase the risk of central nervous system stimulation and seizures when taken with other medicines that lower the seizure threshold. This group includes certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as fenbufen.


Q: Is it okay to drink coffee while taking Toro?

Official clinical studies have examined the potential interaction between Ofloxacin and caffeine. These studies indicate that Ofloxacin does not significantly change the elimination or maximum concentration of caffeine in the body.


Q: Does Toro interact with birth control pills?

Some evidence suggests that antibiotics, including Ofloxacin, may potentially reduce the effectiveness of oral contraceptives that contain ethinyl estradiol. Official references often suggest that, in the event of potential reduced effectiveness, an additional or alternative method of birth control may be considered.


Q: Are there any specific laboratory tests required while taking Toro?

Official warnings regarding drug interactions state that Toro can increase the anticoagulant (blood-thinning) effect of medicines like warfarin. Patients taking warfarin may require closer monitoring of their PT/INR blood tests to prevent complications.


Q: Can I use Toro if I am fasting?

Official regulatory information on the administration of the oral tablet states that it may be taken with or without food. However, it must be separated from antacids and other cation-containing products, regardless of whether a patient has eaten.


Q: Are there any specific foods that increase the absorption of Toro?

Official drug documents state that taking the oral tablet with food does not significantly affect the maximum concentration or the overall absorption of the drug into the body.


Q: Is it normal to feel tired after starting Toro?

Fatigue is listed as an uncommon or rare effect in official reports of adverse reactions, alongside sleep disorders such as insomnia and nightmares. If fatigue is experienced, it is listed as an uncommon finding associated with systemic fluoroquinolones.


Q: Does Toro affect my ability to drive or operate machinery?

Official documentation notes that the drug may cause neurological effects such as dizziness and headache. Patients should be mindful of how the medication affects them before undertaking activities that require mental alertness, such as driving or operating machinery.


Q: Can Toro be crushed or split?

The tablets are film-coated. Specialized pharmacy sources describe that film-coated tablets can potentially be dispersed in water or crushed and mixed with soft food. If alteration is needed, it is typically undertaken only under the explicit guidance of a healthcare professional, acknowledging the potential for a bitter taste.


Q: Does Toro have a bitter taste if dissolved?

Sources that describe alternative administration methods for the film-coated tablet (such as crushing or mixing with liquid) often note that the resulting solution or mixture will have a bitter taste.

How should Toro be stored and disposed of?

How to Store and Dispose of Toro (Ofloxacin)

Official labeling mandates specific conditions to maintain the stability and integrity of Ofloxacin (Toro).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Environment Keep the medicine away from excess heat and moisture and protect from light. The product must not be frozen.
Container Keep Ofloxacin in the original container, which must remain tightly closed.
Child Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Outdated or no-longer-needed Ofloxacin must not be saved. Unused or expired medication should be disposed of properly by consulting a healthcare professional or pharmacist. For single-dose topical containers, discard any unused solution immediately after application.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Toro found in:

A-Z Index: